11-13 June 2019



BrightGene: Exhibitor

BrightGene is a R&D driving pharmaceutical company focus on niche specialty generics and intermediates, with high tech barrier, such as multi-chiral and fermentation.Our manufacturing sites have been approved by FDA EDQM PMDA KFDA and CFDA.

We have full pipeline in ADC cytotoxic payloads, its starting material, and linkers:

  1. Maytansinoids: Ansamitocin P3, DM1 DM4 DM1-SMCC
  2. Auristatins: MMAE MMAF and intermediates, Vc-MMAE
  3. Calicheamicin